Targeted delivery of therapeutic enzymes

Journal of Drug Delivery Science and Technology

Volumn 19, Issue 5, 2009, Pages 311-320

  Maximov, V ^a   Reukov, V ^a   Vertegel, A A ^a  

^a AMRL   (United States)

Author keywords

Antibody; Antimicrobial enzymes; Antioxidant enzymes; Targeted delivery; Therapeutic enzymes; Thrombolysis

Indexed keywords

ALTEPLASE; CARBOXYMETHYLCELLULOSE; FIBRIN ANTIBODY; LIPOSOME; LYSOZYME; NANOPARTICLE; POLYGLACTIN; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOKINASE; SUPEROXIDE DISMUTASE; THROMBIN; UROKINASE;

ANTIBACTERIAL ACTIVITY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; CENTRAL NERVOUS SYSTEM; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RELEASE; ENZYME ACTIVITY; ENZYME THERAPY; ERYTHROCYTE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HYDROGEL; IMMUNOGENICITY; INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; WOUND; WOUND HEALING;

EID: 70350071748     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(09)50066-4     Document Type: Review

References (109)

1. Vellard M. - The enzyme as drug: application of enzymes as pharmaceuticals. - Current Opinion in Biotechnology, 14, 444-450, 2003.
2. Mumtaz S., Bachhawat B.K. (Eds.) - Enzyme Engineering and Its Application in Lysosomal Storage Disease. - Blackwell Science Ltd., 1992, pp. 1055-1060
3. Torchilin V.P. (Ed.) - DrugTargeting. - Elsevier Science Bv, 2000, pp. S81-S91.
4. Takakura Y., Hashida M. - Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. - Pharmaceutical Research, 13, 820-831, 1996. (Pubitemid 26227738)
5. Vaissiere C., Le Cabec V., Maridonneau-Parini I. - NADPH oxidase is functionally assembled in specific granules during activation of human neutrophils. - J. Leukoc. Biol., 65, 629-634, 1999. (Pubitemid 29227054)
6. Griendling K.K., Sorescu D., Ushio-Fukai M. - NAD(P)H oxidase, Role in cardiovascular biology and disease. - CircRes., 86, 494-501, 2000. (Pubitemid 30165039)
7. Baldwin A.S. - The NF-kappa B and I kappa B proteins: new discoveries and insights. - Ann. Rev. Immunol., 14, 649-683, 1996. (Pubitemid 26130197)
8. Shenkar R., Schwartz M.D., Terada L.S., Repine J.E., McCord J., Abraham E. - Hemorrhage activates NF-kappa B in murine lung mononuclear cells in vivo. - American Journal of Physiology-Lung Cellular and Molecular Physiology, 270, L729-L35, 1996. (Pubitemid 26182574)
9. Blackwell T.S., Christman J.W. - The role of nuclear factor-kappa b in cytokine gene regulation. - Am. J. Respir. Cell Mol. Biol., 17, 1, 3-9, 1997. (Pubitemid 127500814)
10. Young R.P., Hopkins R., Black P.N., Eddy C., Wu L., Gamble G.D. et al. - Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. - Thorax, 61, 394-399, 2006. (Pubitemid 43723321)
11. Yasui K., Baba A. - Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. - Inflamm. Res., 55, 359-63, 2006. (Pubitemid 44825292)
12. Garcia-Gonzalez A., Herrera-Abarca J., Ochoa J.L. - Effect of superoxide dismutase from bovine erythrocytes on different activity parameters in adjuvant-induced arthritis. - Archives of Medical Research, 30, 132-137, 1999. (Pubitemid 29255688)
13. Skorohod N., Yeates D.B. - Superoxide dismutase failed to attenuate allergen-induced nasal congestion in ragweed-sensitized dogs. - Journal of Applied Physiology, 98, 1478-1486, 2005. (Pubitemid 40396526)
14. Assa'ad A.H., Ballard E.T., Sebastian K.D., Loven D.P., Boivin G.P., Lierl M.B. - Effect of superoxide dismutase on a rabbit model of chronic allergic asthma. - Annals of Allergy Asthma & Immunology, 80, 215-224, 1998. (Pubitemid 28145307)
15. Fujita T., Nishikawa M., Tamaki C., Takakura Y., Hashida M., Sezaki H. - Targeted delivery of human recombinant superoxide-dismutase by chemical modification with monosaccharide and polysaccharide derivatives. - Journal of Pharmacology and Experimental Therapeutics, 263, 971-978, 1992. (Pubitemid 23157168)
16. Takakura Y., Masuda S., Tokuda H., Nishikawa M., Hashida M. - Targeted delivery of superoxide-dismutase to macrophages via mannose receptor-mediated mechanism. - Biochemical Pharmacology, 47, 853-858, 1994. (Pubitemid 24087414)
17. Francis J.W., Hosler B.A., Brown R.H., Fishman P.S. - Cuzn superoxide-dismutase (Sod-1)-tetanus toxin fragment-C hybrid protein for targeted delivery of Sod-1 to neuronal cells. - Journal of Biological Chemistry, 270, 15434-15442, 1995.
18. Tsuchiya M., Thompson D.F.T., Suzuki Y.J., Cross C.E., Packer L. - Superoxide formed from cigarette-smoke impairs polymorphonuclear leukocyte active oxygen generation activity. - Archives of Biochemistry and Biophysics, 299, 30-37, 1992.
19. Nishikawa M., Kudo M., Kakemizu N., Ikeda H., Okubo T. - Role of superoxide anions in airway hyperresponsiveness induced by cigarette smoke in conscious Guinea pigs. - Lung, 174, 279-289, 1996. (Pubitemid 26287168)
20. Lehucker-Michel M.P., Lesgards J.F., Delubac O., Stocker P., Durand P., Prost M. - Oxidative stress and human disease: current knowledge and perspectives for prevention. - Presse Med., 30, 1076-1081, 2001. (Pubitemid 32612394)
21. Rahman I., MacNee W. - Role of oxidants/antioxidants in smoking-induced lung diseases. - Free Radical Biology and Medicine, 21, 669-681, 1996. (Pubitemid 26331096)
22. Das S., Horowitz S., Robbins C.G., El-Sabban M.E., Sahgal N., Davis J.M. - Intracellular uptake of recombinant superoxide dismutase after intratracheal administration. - American Journal of Physiology-Lung Cellular and Molecular Physiology, 274, L673-L7, 1998. (Pubitemid 28259437)
23. Langenback E.G., Davis J.M., Robbins C., Sahgal N., Perry R.J., Simon S.R. - Improved pulmonary distribution of recombinant human Cu/Zn superoxide dismutase, using a modified ultrasonic nebulizer. - Pediatric Pulmonology, 27, 124-129, 1999. (Pubitemid 29104451)
24. Min Y.-G., Ohyama M., Lee K.S., Rhee C.-S., Oh S.H., Sung M.-W. et al. - Effects of free radicals on ciliary movement in the human nasal epithelial cells. - Auris Nasus Larynx, 26, 159-163, 1999. (Pubitemid 29156269)
25. Ueda J., Starr M.E., Takahashi H., Du J., Chang L.Y., Crapo J.D. et al. - Decreased pulmonary extracellular superoxide dismutase during systemic inflammation. - Free Radical Biology and Medicine, 45, 897-904, 2008.
26. Giovagnoli S., Blasi P., Ricci M., Rossi C. - Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery. - AAPS Pharmscitech., 5, 2004. (Pubitemid 41086270)
27. Giovagnoli S., Luca G., Casaburi I., Blasi P., Macchiarulo G., Ricci M. et al. - Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. - Journal of Controlled Release, 107, 65-77, 2005.
28. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M. et al. - Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. - Toxicology and Applied Pharmacology, 215, 100-108, 2006. (Pubitemid 44118400)
29. Lee S., Yang S.C., Heffernan M.J., Taylor W.R., Murthy N. - Polyketal microparticles: a new delivery vehicle for superoxide dismutase. - Bioconjugate Chemistry, 18, 4-7, 2007. (Pubitemid 46145988)
30. Gongora M.C., Lob H.E., Landmesser U., Guzik T.J., Martin W.D., Ozumi K. et al. - Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air, A potential mechanism underlying adult respiratory distress syndrome. - Am. J. Pathol., 173, 915-926, 2008.
31. Chiumiento A., Lamponi S., Barbucci R., Dominguez A., Perez Y., Villalonga R. - Immobilizing Cu,Zn-superoxide dismutase in hydrogels of carboxymethylcellulose improves its stability and wound healing properties. - Biochemistry-Moscow, 71, 1324-1328, 2006. (Pubitemid 44957913)
32. Salmon M., ScheelToellner D., Huissoon A.P., Pilling D., Shamsadeen N., Hyde H. et al. - Inhibition of T cell apoptosis in the rheumatoid synovium. - J. Clin. Invest., 99, 439-446, 1997.
33. Verburg R.J., Flierman R., Sont J.K., Ponchel F., van Dreunen L., Levarht E.W. et al. - Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. - Ann. Rheum. Dis., 64, 1397-1405, 2005. (Pubitemid 41623847)
34. Calder P.C. - In: Proceedings of Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease': PUFA, Inflammatory Processes and Rheumatoid Arthritis, Session 3, Cambridge Univ. Press, 2008, pp. 409-418
35. Mirshafiey A., Mohsenzadegan M. - The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. - Iran J. Allergy Asthma Immunol., 7, 195-202, 2008.
36. Hoedtschmidt S., Schneider B., Kalbhen D.A. - Histomorphological studies on the effect of recombinant human superoxide-dismutase in biochemically induced osteoarthritis. - Pharmacology, 47, 252-260, 1993. (Pubitemid 23256325)
37. Kaipel M., Wagner A., Wassermann E., Vorauer-Uhl K., Kellner R., Redl H. et al. - Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. - J. Aerosol Med. Pulm. Drug Deliv., 21, 281-290, 2008.
38. Lee S.M., Murthy N. - Targeted delivery of catalase and superoxide dismutase to macrophages using folate. - Biochemical and Biophysical Research Communications, 360, 275-279, 2007.
39. Gaspar M.M., Boerman O.C., Laverman P., Corvo M.L., Storm G., Cruz M.E.M. - Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. - Journal of Controlled Release, 117, 186-195, 2007. (Pubitemid 46172500)
40. Cruz M.E.M., Gaspar M.M., Martins M.B.F., Corvo M.L. - Liposomal superoxide dismutases and their use in the treatment of experimental arthritis. - Methods in Enzymology, 395-413, 2005.
41. Corvo M.L., Boerman O.C., Oyen W.J.G., Van Bloois L., Cruz M.E.M., Crommelin D.J.A. et al. - Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. - Biochimica et Biophysica Acta-Biomembranes, 1419, 325-334, 1999.
42. Gaspar M.M., Martins M.B., Corvo M.L., Cruz M.E.M. - Design and characterization of enzymosomes with surface-exposed superoxide dismutase. - Biochimica et Biophysica Acta-Biomembranes, 1609, 211-217, 2003. (Pubitemid 36120729)
43. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., Harrison D.G. - Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. - Circulation, 95, 588-593, 1997. (Pubitemid 27063033)
44. Luisa Corvo M., Jorge J.C.S., van't Hof R., Cruz M.E.M., Crommelin D.J.A., Storm G. - Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. - Biochimica et Biophysica Acta (BBA) - Biomembranes, 1564, 227-236, 2002. (Pubitemid 34717889)
45. Reddy M.K., Wu L., Kou W., Ghorpade A., Labhasetwar V. - Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. - Appl. Biochem. Biotechnol., 151, 565-577, 2008.
46. Begley D.J. - Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. - Pharmacology & Therapeutics, 104, 29-45, 2004.
47. Schroeder U., Sommerfeld P., Ulrich S., Sabel B.A. - Nanoparticle technology for delivery of drugs across the blood-brain barrier. - Journal of Pharmaceutical Sciences, 87, 1305-1307, 1998. (Pubitemid 28514132)
48. Reukov V., Olbrich J., Satishkumar R., Vertegel A. - Protein-nanoparticle conjugates as a potential therapeutic agents for treatment of secondary spinal cord injury. - Proceedings of the MRS 2007 Fall Meeting, Boston, MA, Materials Research Society, 2007, pp. 6-16.
49. Weitz J.I., Stewart R.J., Fredenburgh J.C. - Mechanism of action of plasminogen activators. -Thrombosis and Haemostasis, 82, 974-982, 1999.
50. Haber E., Quertermous T., Matsueda G.R., Runge M.S.- Innovative approaches to plasminogen-activator therapy. - Science, 243, 51-56, 1989.
51. Huber K., Runge M.S., Bode C., Gulba D. - Thrombolytic therapy in acute myocardial infarction, Update 1996. - Annals of Hematology, 73, S29-S38, 1996. (Pubitemid 26325363)
52. Chazov E.I., Matveeva L.S., Mazaev A.V., Sargin K.E., Sadovskaya G.V., Ruda M.Y. - Intracoronary administration of fibrinolysin in acute myocardial infarction. - Terapevticheskii Arkhiv., 48, 8-19, 1976.
53. Torchilin V.P. - Targeting of thrombolytic agents, Current state of knowledge and perspectives. - Plasminogen Activation in Fibrinolysis, in Tissue Remodeling, and in Development, 667, 404-416, 1992.
54. Haber E. - Antibody targeting as a strategy in thrombolysis. - In: Khaw B.A., Narula J., Strauss H.W. Eds., Monoclonal Antibodies in Cardiovascular Diseases, Malvern, Lea and Febiger, 1994, pp. 187-197
55. Bode C., Matsueda G.R., Hui K.Y., Haber E. - Antibody-directed urokinase, A specific fibrinolytic agent. - Science, 229, 765-767, 1985. (Pubitemid 15049820)
56. Bode C., Runge M.S., Newell J.B., Matsueda G.R., Haber E. - Characterization of an antibody-urokinase conjugate, A plasminogen-activator targeted to fibrin. - Journal of Biological Chemistry, 262, 10819-10823, 1987. (Pubitemid 17127051)
57. Runge M.S., Bode C., Matsueda G.R., Haber E. - Antibody-enhanced thrombolysis, Targeting of tissue plasminogen-activator in vivo. - Proceedings of the National Academy of Sciences of the United States of America, 84, 7659-7662, 1987.
58. Love T.W., Quertermous T., Runge M.S., Michelson K.D., Matsueda G.R., Haber E. - Attachment of an antifibrin antibody to the amino-terminus of tissue-type plasminogen-activator impairs stimulation by fibrin. - Fibrinolysis, 8, 326-332, 1994.
59. Bode C., Meinhardt G., Runge M.S., Freitag M., Nordt T., Arens M. et al. - Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet-aggregation. - Circulation, 84, 805-813, 1991.
60. Underwood M.J., Pringle S., Bono D.P.D. - Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells. - British Journal of Surgery, 79, 915-917, 1992.
61. Schnee J.M., Runge M.S., Matsueda G.R., Hudson N.W., Seidman J.G., Haber E. et al. - Construction and expression of a recombinant antibody-targeted plasminogen-activator. - Proceedings of the National Academy of Sciences of the United States of America, 84, 6904-6908, 1987.
62. Charpie J.R., Runge M.S., Matsueda G.R., Haber E. - A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase. - Biochemistry, 29, 6374-6378, 1990. (Pubitemid 20210786)
63. Branscomb E.E., Runge M.S., Savard C.E., Adams K.M., Matsueda G.R., Haber E. - Bispecific monoclonal-antibodies produced by somatic-cell fusion increase the potency of tissue plasminogen-activator. - Thrombosis and Haemostasis, 64, 260-266, 1990.
64. Neblock D.S., Chang C.H., Mascelli M.A., Fleek M., Stumpo L., Cullen M.M. et al. - Conjugation and evaluation of 7e3xp4b6, a chemically cross-linked bispecific F(Ab′)2 antibody which inhibits platelet-aggregation and localizes tissue plasminogen-activator to the platelet surface. - Bioconjugate Chemistry, 3, 126-131, 1992.
65. Imura Y., Stassen J.M., Kurokawa T., Iwasa S., Lijnen H.R., Collen D. - Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antobidy against fibrin and against u-PA in baboons. - Blood, 79, 2322-2329, 1992.
66. Liang J.F., Park Y.J., Song H., Li Y.T., Yang V.C. - Attempts, A heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. - Journal of Controlled Release, 72, 145-156, 2001. (Pubitemid 32522352)
67. Naik S.S., Liang J.F., Park Y.J., Lee W.K., Yang V.C. - Application of "Attempts" for drug delivery. - Journal of Controlled Release, 101, 35-45, 2005.
68. Liang J.F., Li Y.T., Connell M.E., Yang V.C. - Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug-delivery system. - AAPS Pharmsci., 2, art. No.7, 2002.
69. Liang J.F., Li Y.T., Song H., Park Y.J., Naik S.S., Yang V.C. Attempts, A heparin/protamine-based delivery system for enzyme drugs. - Journal of Controlled Release, 78, 67-79, 2002. (Pubitemid 34081854)
70. Maksimenko A.V., Torchilin V.P. - Water-soluble urokinase derivatives with increased affinity to the fibrin clot. - Thrombosis Research, 38, 289-295, 1985.
71. Maksimenko A.V., Samarenko M.B., Petrov A.D., Tischenko E.G., Abramova V.V. - Efficacy of thrombolytic action of modified urokinase upon bolus intravenous injection. - Khim Pharm. Z., 2, 117-119, 1990.
72. Maksimenko A.V., Rusetskii A.N., Torchilin V.P. - Fibrinolytic action of an enzyme preparation covalently bound to modified thrombin. - Byulleten' Eksperimental'noi Biologii i Meditsiny, 103, 35-38, 1987.
73. Nakayama Y., Miyazaki W., Shinohara M., inventors, Otsuka Pharmaceutical Co., Ltd., assignee. - Urokinase-plasmin complex adsorbable by fibrin and process for preparing same. - US Patent 4545988, Oct. 8, 1985.
74. Nakayama Y., Shinohara M., Tani T., Kawaguchi T., Furuta T., Izawa T. et al. - The plasmin heavy-chain - urokinase conjugate - a specific thrombolytic agent. - Thrombosis and Haemostasis, 56, 364-370, 1986. (Pubitemid 17092588)
75. Orekhova N.M., Akchurin R.S., Belyaev A.A., Smirnov M.D., Ragimov S.E., Orekhov A.N. - Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red-cells. - Thrombosis Research, 57, 611-616, 1990.
76. Driscoll CE, Morris R.M., Senyei A.E., Widder K.J., Heller G.S. - Magnetic targeting of microspheres in blood-flow. - Microvascular Research, 27, 353-369, 1984.
77. Torchilin V.P., Papisov M.I., Smirnov V.N. - Magnetic Sephadex as a carrier for enzyme immobilization and drug targeting. - Journal of Biomedical Materials Research, 19, 461-466, 1985.
78. Alexiou C., Arnold W., Hulin P., Klein R.J., Renz H., Parak F.G. et al. - Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. - Journal of Magnetism and Magnetic Materials, 225, 187-193, 2001. (Pubitemid 32335295)
79. Ma Y.H., Hsu Y.W., Chang Y.J., Hua M.Y., Chen J.P., Wu T. - Intra-arterial application of magnetic nanoparticles for targeted thrombolytic therapy: a rat embolic model. - Journal of Magnetism and Magnetic Materials, 311, 342-346, 2007.
80. Gregoriadis G., Florence A.T., Patel H.M. (Eds.) - Liposomes in Drug Delivery. - Harwood Academic Publishers, Langhorne, PA, 1993.
81. nd ed., CRC Press, Boca Raton, FL, 1993, pp. 1-3.
82. Tiukinhoy-Laing S.D., Huang S.L., Klegerman M., Holland C.K., McPherson D.D. - Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. - Thrombosis Research, 119, 777-784, 2007. (Pubitemid 46441423)
83. Murciano J.C., Medinilla S., Eslin D., Atochina E., Cines D.B., Muzykantov V.R. - Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. - Nature Biotechnology, 21, 891-896, 2003. (Pubitemid 36936194)
84. Heredia K.L., Maynard H.D. - Synthesis of protein-polymer conjugates. - Organic & Biomolecular Chemistry, 5, 45-53, 2007.
85. Crommelin D.J.A., Storm G., Jiskoot W., Stenekes R., Mastrobattista E., Hennink W.E. - Nanotechnological approaches for the delivery of macromolecules. - Journal of Controlled Release, 87, 81-88, 2003.
86. Kim J., Grate J.W., Wang P. - Nanostructures for enzyme stabilization. - Chemical Engineering Science, 61, 1017-1026, 2006.
87. Asuri P., Karajanagi S.S., Vertegel A.A., Dordick J.S., Kane R.S. - Enhanced stability of enzymes adsorbed onto nanoparticles. - Journal of Nanoscience and Nanotechnology, 7, 1675-1678, 2007.
88. Karajanagi S.S., Vertegel A.A., Kane R.S., Dordick J.S. - Structure and function of enzymes adsorbed onto single-walled carbon nanotubes. - Langmuir, 20, 11594-11599, 2004. (Pubitemid 40049633)
89. Vertegel A.A., Siegel R.W., Dordick J.S. - Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. - Langmuir, 20, 6800-6807, 2004.
90. Yurko Y., Maximov V., Andreozzi E., Thompson G.L., Vertegel A.A. - Design of biomedical nanodevices for dissolution of blood clots. - Materials Science & Engineering: C (Materials for Biological Applications), 737-741, 2009.
91. Fernandez Guerrero M.L., Ramos J.M., Marrero J., Cuenca M., Fernandez Roblas R., De Gorgolas M. - Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. - International Journal of Infectious Diseases, 7, 46-52, 2003. (Pubitemid 36358876)
92. Zaiou M. - Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. - Journal of Molecular Medicine, 85, 317-329, 2007.
93. Niyonsaba F., Ogawa H. - Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. - Journal of Dermatological Science, 40, 157-168, 2005. (Pubitemid 41728963)
94. Kreuter J., Speiser P.P. - New adjuvants on a polymethylmethacrylate base. - Infection and Immunity, 13, 204-210, 1976.
95. Henrymichelland S., Alonso M.J., Andremont A., Maincen P., Sauzieres J., Couvreur P. - Attachment of antibiotics to nanoparticles, Preparation, drug-release and antimicrobial activity in vitro. - International Journal of Pharmaceutics, 35, 121-127, 1987. (Pubitemid 17016885)
96. Page-Clisson M.E., Pinto-Alphandary H., Chachaty E., Couvreur P., Andremont A. - Drug targeting by polyalkylcyanoacrylate is not efficient against persistent Salmonella. - Pharmaceutical Research, 15, 544-549, 1998. (Pubitemid 28214946)
97. Esmaeili F., Hosseini-Nasr M., Rad-Malekshahi M., Samadi N., Atyabi F., Dinarvand R. - Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. - Nanomedicine-Nanotechnology Biology and Medicine, 3, 161-167, 2007. (Pubitemid 46908907)
98. Salmaso S., Elvassore N., Bertucco A, Lante A, Caliceti P. - Nisin-loaded poly-L-lactide nano-particles produced by CO2 anti-solvent precipitation for sustained antimicrobial activity. - International Journal of Pharmaceutics, 287, 163-173, 2004. (Pubitemid 39487254)
99. Qu L.W., Luo P.G., Taylor S., Lin Y., Huang W.J., Anyadike N. et al. - Visualizing adhesion-induced agglutination of Escherichia coli with mannosylated nanoparticles. - Journal of Nanoscience and Nanotechnology, 5, 319-322, 2005.
100. Luo P.J.G., Tzeng T.R., Qu L.W., Lin Y., Caldwell E., Latou R.A. et al. - Quantitative analysis of bacterial aggregation mediated by bioactive nanoparticles. - Journal of Biomedical Nanotechnology, 1, 291-296, 2005.
101. Qu L.W., Gu L.R., Li H.P., Taylor S., Elkin T., Luo P.J.G. et al. - Galactosylated polymeric nanoparticles: synthesis and adhesion interactions with Escherichia coli. - Journal of Biomedical Nanotechnology, 1, 61-67, 2005.
102. Yang H., Qu L.W., Wimbrow A., Jiang X.P., Sun Y.P. - Enhancing antimicrobial activity of lysozyme against Listeria monocytogenes using immunonanoparticles. - Journal of Food Protection, 70, 1844-1849, 2007.
103. Satishkumar R., Vertegel A. - Charge-directed targeting of antimicrobial protein-nanoparticle conjugates. - Biotechnology and Bioengineering, 100, 403-412, 2008. (Pubitemid 351792916)
104. Reddy J.A., Allagadda V.M., Leamon C.P. - Targeting therapeutic and imaging agents to folate receptor positive tumors. - Current Pharmaceutical Biotechnology, 6, 131-150, 2005.
105. NiculescuDuvaz I., Springer C.J. - Antibody-directed enzyme prodrug therapy (ADEPT): a review. - Advanced Drug Delivery Reviews, 26, 151-172, 1997. (Pubitemid 27289531)
106. Napier M.P., Sharma S.K., Springer C.J., Bagshawe K.D., Green A.J., Martin J. et al. - Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. - Clinical Cancer Research, 6, 765-772, 2000. (Pubitemid 30159328)
107. Begent R.H.J., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P. et al. - Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. - Nature Medicine, 2, 979-984, 1996.
108. Genencor International website [cited; available from: http://www.genencor.com/wt/gcor/adv-therapeutics].
109. Mayer A., Francis R.J., Sharma S.K., Tolner B., Springer C.J., Martin J. et al. - A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. - Clinical Cancer Research, 12, 6509-6516, 2006. (Pubitemid 44799725)